EC Healthcare Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
EC Healthcare wird ein Gewinn- und Umsatzwachstum von 126.4% bzw. 6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 108.4% pro Jahr wachsen soll.
Wichtige Informationen
126.4%
Wachstumsrate der Gewinne
108.4%
EPS-Wachstumsrate
| Consumer Services Gewinnwachstum | 21.4% |
| Wachstumsrate der Einnahmen | 6.0% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 04 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends
Nov 13
Little Excitement Around EC Healthcare's (HKG:2138) Revenues As Shares Take 31% Pounding
Sep 05EC Healthcare (HKG:2138) Might Be Having Difficulty Using Its Capital Effectively
Jul 26EC Healthcare (HKG:2138) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 13When Should You Buy EC Healthcare (HKG:2138)?
Apr 26Is EC Healthcare (HKG:2138) A Risky Investment?
Feb 07Slammed 26% EC Healthcare (HKG:2138) Screens Well Here But There Might Be A Catch
Dec 24EC Healthcare's (HKG:2138) Dividend Is Being Reduced To HK$0.005
Dec 08Here's What's Concerning About EC Healthcare's (HKG:2138) Returns On Capital
Dec 01At HK$3.13, Is EC Healthcare (HKG:2138) Worth Looking At Closely?
Sep 15EC Healthcare (HKG:2138) Is Paying Out A Dividend Of HK$0.042
Aug 24Is EC Healthcare (HKG:2138) Using Too Much Debt?
Aug 10EC Healthcare (HKG:2138) Has Announced A Dividend Of HK$0.042
Jul 14EC Healthcare (HKG:2138) Will Pay A Dividend Of HK$0.042
Jun 26Is There Now An Opportunity In EC Healthcare (HKG:2138)?
Jun 15Be Wary Of EC Healthcare (HKG:2138) And Its Returns On Capital
May 12Is EC Healthcare (HKG:2138) Potentially Undervalued?
Mar 08EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends
Feb 03EC Healthcare (HKG:2138) Is Paying Out Less In Dividends Than Last Year
Dec 20Is Now An Opportune Moment To Examine EC Healthcare (HKG:2138)?
Oct 25EC Healthcare (HKG:2138) Is Reinvesting At Lower Rates Of Return
Sep 20EC Healthcare's (HKG:2138) Dividend Will Be Reduced To HK$0.042
Sep 01EC Healthcare's (HKG:2138) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 28EC Healthcare's (HKG:2138) Dividend Will Be Reduced To HK$0.042
Jul 14EC Healthcare (HKG:2138) Is Reducing Its Dividend To HK$0.042
Jun 26When Should You Buy EC Healthcare (HKG:2138)?
May 26EC Healthcare (HKG:2138) Will Be Hoping To Turn Its Returns On Capital Around
Apr 18Is It Too Late To Consider Buying EC Healthcare (HKG:2138)?
Feb 24EC Healthcare (HKG:2138) Could Easily Take On More Debt
Feb 11Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2026 | 4,749 | 17 | N/A | N/A | 1 |
| 3/31/2025 | 4,443 | 7 | N/A | 897 | 1 |
| 3/31/2024 | 4,211 | -19 | 528 | 689 | N/A |
| 12/31/2023 | 4,157 | -11 | 422 | 709 | N/A |
| 9/30/2023 | 4,104 | -4 | 317 | 729 | N/A |
| 6/30/2023 | 3,989 | 33 | 255 | 667 | N/A |
| 3/31/2023 | 3,875 | 70 | 193 | 605 | N/A |
| 12/31/2022 | 3,622 | 93 | 162 | 499 | N/A |
| 9/30/2022 | 3,369 | 117 | 132 | 392 | N/A |
| 6/30/2022 | 3,144 | 157 | 240 | 500 | N/A |
| 3/31/2022 | 2,920 | 198 | 348 | 608 | N/A |
| 12/31/2021 | 2,823 | 253 | 479 | 684 | N/A |
| 9/30/2021 | 2,727 | 309 | 610 | 760 | N/A |
| 6/30/2021 | 2,404 | 251 | 541 | 690 | N/A |
| 3/31/2021 | 2,080 | 193 | 472 | 621 | N/A |
| 12/31/2020 | 1,854 | 163 | 487 | 597 | N/A |
| 9/30/2020 | 1,627 | 133 | 503 | 573 | N/A |
| 6/30/2020 | 1,788 | 210 | 505 | 574 | N/A |
| 3/31/2020 | 1,949 | 287 | 507 | 576 | N/A |
| 12/31/2019 | 2,023 | 325 | 273 | 452 | N/A |
| 9/30/2019 | 2,098 | 364 | 40 | 327 | N/A |
| 6/30/2019 | 1,975 | 363 | -5 | 283 | N/A |
| 3/31/2019 | 1,852 | 361 | -49 | 238 | N/A |
| 12/31/2018 | 1,715 | 355 | 108 | 278 | N/A |
| 9/30/2018 | 1,578 | 348 | 265 | 317 | N/A |
| 6/30/2018 | 1,450 | 314 | 269 | 320 | N/A |
| 3/31/2018 | 1,322 | 279 | 272 | 324 | N/A |
| 12/31/2017 | 1,253 | 266 | N/A | 302 | N/A |
| 9/30/2017 | 1,183 | 253 | N/A | 280 | N/A |
| 6/30/2017 | 1,079 | 227 | N/A | 230 | N/A |
| 3/31/2017 | 975 | 201 | N/A | 180 | N/A |
| 12/31/2016 | 878 | 170 | N/A | 123 | N/A |
| 9/30/2016 | 780 | 139 | N/A | 66 | N/A |
| 6/30/2016 | 744 | 144 | N/A | 71 | N/A |
| 3/31/2016 | 708 | 149 | N/A | 76 | N/A |
| 12/31/2015 | 688 | 166 | N/A | 105 | N/A |
| 9/30/2015 | 668 | 183 | N/A | 134 | N/A |
| 6/30/2015 | 645 | 179 | N/A | 146 | N/A |
| 3/31/2015 | 621 | 174 | N/A | 159 | N/A |
| 3/31/2014 | 490 | 81 | N/A | 145 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 2138 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.3%).
Ertrag vs. Markt: 2138 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: 2138 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: 2138Die Einnahmen des Unternehmens (6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Hong Kong (7.8% pro Jahr).
Hohe Wachstumseinnahmen: 2138Die Einnahmen des Unternehmens (6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 2138 in 3 Jahren voraussichtlich hoch sein wird